Table 1.
Patients’ clinical characteristics and laboratory data
| Features | Cases (n = 680) | Healthy (n = 164) | P value |
|---|---|---|---|
| Male/Female, n | 465/215 | 76/88 | |
| Age (years) | 54.9 ± 11.0 | 56.8 ± 14.8 | 0.02 |
| IFN therapy N (%) | 291 (42.8%) | 0 (0.00%) | |
| Habitual alcohol intake N (%) | 275 (40.4%) | ||
| Body mass index | 23.6 ± 3.1 | 24.0 ± 3.1 | 0.114 |
| Platelet count (×109/l) | 166.7 ± 74.8 | 228.3 ± 45.1 | <0.001 |
| AST (15–46 IU/l) | 49.2 ± 39.9 | 26.4 ± 10.2 | <0.001 |
| ALT (0–40 IU/l) | 37.7 ± 43.8 | 23.7 ± 15.1 | 0.011 |
| GGT (12–73 IU/l) | 63.7 ± 105.3 | 27.2 ± 27.7 | <0.001 |
| AFP (0–6.2 IU/l) | 7.46 ± 33.9 | ||
| HCV genotype N (%) | |||
| 1b | 126 (18.5%) | ||
| 2a | 94 (13.8%) | ||
| 1b/2a | 2 (0.3%) | ||
| Unknown | 459 (67.4%) | ||
| Fibrosis markers | |||
| APRI | 1.06 ± 2.72 | 0.30 ± 0.13 | <0.001 |
| FIB4 | 4.84 ± 12.05 | 1.33 ± 0.55 | <0.001 |
| AST/ALT ratio | 2.62 ± 2.80 | 1.45 ± 1.43 | <0.001 |
| GPR | 0.58 ± 1.21 | 0.12 ± 0.12 | <0.001 |
| M2BPGi | 1.57 ± 2.28 | 0.38 ± 0.23 | <0.001 |
| Fibrosis stage (0 ~ 1/2 ~ 3/4) | 437/175/68 | 155/9/0 | |